NCT06473909

Combination of Steroid and Humanized CD25 Monoclonal Antibody as First-line Therapy for aGVHD

An Exploratory Clinical Study on the Efficacy and Safety of Humanized CD25 Monoclonal Antibody Combined With Glucocorticoid in the First-line Treatment of Acute Graft-versus-host Disease (aGVHD) After Allo-HSCT

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The first-line treatment of acute graft-versus-host disease with humanized CD25 monoclonal antibody combined with glucocorticoid was used to study the remission rate of acute graft-versus-host disease, the cumulative incidence and remission rate of severe acute graft-versus-host disease, GVHD-free survival rate, all-cause mortality and quality of life evaluation, and safety evaluation for prevention programs.

Conditions

• Acute Graft Versus Host Disease

Interventions

Type	Name	Description
DRUG	CD25 antibody combined glucocorticoid as first-line treatment	CD25 antibody combined glucocorticoid as first-line treatment

Timeline

• Start date: 2024-07-01
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2024-06-25
• Last updated: 2024-06-25